bioRxiv · 10.64898/2026.01.27.701990
Experimental Trypanosoma cruzi infection cured with a mechanistically distinct drug combination
Abstract
Infections with the protozoan parasite Trypanosoma cruzi are widespread in the Americas and can lead to severe cardiac and/or gastrointestinal pathology. Current treatments are limited to monotherapies characterised by prolonged dosing regimens, disputed efficacy and toxic side-effects. Here, we demonstrate that short duration co-administration of well-tolerated sub-efficacious oral doses of the parasite-selective proteasome inhibitor GNF6702 and the pro-drug benznidazole produce parasitological cure in an experimental model of chronic Chagas disease.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Francisco, A. F., Olmo, F., Escudie, F., Chatelain, E., Kelly, J. M.. 2026-01-27. Experimental Trypanosoma cruzi infection cured with a mechanistically distinct drug combination. https://doi.org/10.64898/2026.01.27.701990
Cite the original work for its findings. Save a collection to share your selection of sources.